Novartis/Incyte Move Forward With JAK Inhibitor For MF
This article was originally published in The Pink Sheet Daily
Executive Summary
Results from a second Phase III study provides further evidence that '424 is effective in treating the rare blood cancer.
You may also be interested in...
Incyte’s Jakafi Gets Additional Claim Based On Patient-Reported Outcomes
Jakafi is the first approved treatment for myelofibrosis, a rare bone marrow cancer, but Incyte will also be able to claim efficacy against the symptoms of the disease thanks to data in labeling from a patient-reported outcomes tool.
Onyx Walks Away From Option To Develop S*BIO JAK2 Inhibitors; S*BIO CEO Looks To Chart A New Course
Although anxious to move forward into Phase III trials, Singapore-based S*BIO announced May 4 that partner Onyx Pharmaceuticals will not exercise its options to develop S*BIO's JAK2 inhibitors SB1518 and SB1578. The Singapore biotech has regained full rights to the janus kinase inhibitors and will now look for a new partner to help move forward in development
JAK Of All Trades: Janus Kinase Inhibitors Are Ready, Willing And Orally Available For Many Diseases
Orally available, flexible and novel, Janus kinase inhibitors are poised to trigger major treatment shakeups in at least two disease spaces. Two drugs at the head of the JAK pack are close to coming of age – Pfizer Inc.’s tofacitinib and Incyte Corp.’s ‘18424 – and hopes are high, though questions remain about selectivity, long-term side effects and just how far the class can go.